Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Zepbound KwikPen is the only dual-action GLP-1/GIP medication approved for weight management, with the highest average weight loss in clinical trials (22%)
With Qualiphys GLP-1 consultations and nationwide delivery service, your clinic can easily integrate weight loss solutions without additional administrative strain
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
Semaglutide can also be used to control blood sugar levels in patients with type 2 diabetes and is found under the brand name Ozempic
But Ozempic and other GLP-1s work by slowing down absorption